Clinical Trials
43 trialsNCT06955169 2026-05-22
MOMENTUM-1
RTOG Foundation, Inc.
Phase 2 Suspended
NCT04116502 2026-04-28
MITHRIDATE
University of Birmingham
Phase 3 Recruiting
NCT06871410 2026-03-24
Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 1 Recruiting
NCT06930352 2026-03-13
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Ohio State University Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT05526924 2026-03-04
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
University of Chicago
Phase 1 Recruiting
NCT04217356 2026-01-26
ALLO-BAT
University Health Network, Toronto
Active not recruiting
NCT06199557 2025-06-29
HUVAMER
Haukeland University Hospital
Phase 1/2 Recruiting
NCT06005324 2025-06-08
Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer
University of Chicago
Phase 1 Recruiting
NCT03944915 2025-05-11
DEPEND
University of Chicago
Phase 2 Completed
NCT03107182 2025-05-06
OPTIMA-II
University of Chicago
Phase 2 Completed
NCT02258659 2024-09-24
OPTIMA
University of Chicago
Phase 2 Completed
NCT05005182 2024-09-19
Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts
Mayo Clinic
Phase 2 Terminated
NCT01847326 2024-07-31
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer
University of Chicago
Phase 1 Completed
NCT02626715 2024-07-16
Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS
University of Pittsburgh
Phase 2 Completed
NCT01693718 2024-01-29
A Multicenter Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck Cancer
University of Chicago
Phase 2 Completed
NCT01387763 2022-04-27
DALIAH
Odense University Hospital
Phase 3 Completed
NCT02899169 2021-09-08
APL16
First Affiliated Hospital Xi'an Jiaotong University
Phase 3 Unknown
NCT00006119 2021-02-21
Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma
UNICANCER
Phase 2 Completed
NCT03463733 2020-10-08
HUTMZ
Amsterdam UMC, location VUmc
Phase 1 Unknown
NCT00468169 2019-10-09
EPIC
University of Chicago
Phase 2 Completed
NCT01964755 2019-09-23
Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
University of Miami
Phase 2 Terminated
NCT01259856 2019-04-30
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
Icahn School of Medicine at Mount Sinai
Phase 3 Completed
NCT00019474 2018-09-14
Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer
Montefiore Medical Center
Phase 2 Completed
NCT03515018 2018-05-22
HU
First Affiliated Hospital of Harbin Medical University
Phase 3 Unknown
NCT00055874 2018-05-03
Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Heidelberg University
Phase 3 Completed
NCT00117572 2018-04-09
DeCIDE
University of Chicago
Phase 3 Completed
NCT00462735 2018-03-13
Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT01211938 2017-05-16
JANORL2
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2/3 Completed
NCT00978146 2017-04-20
Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors
Children's Hospital of Philadelphia
Phase 2 Withdrawn
NCT00706810 2017-04-13
Combination of Hydroxyurea and Verapamil for Refractory Meningiomas
University of Utah
Phase 2 Completed
NCT00004933 2016-07-04
Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT00387933 2015-10-14
Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma
Duke University
Phase 1 Completed
NCT02480608 2015-06-24
CML2004
University of Leipzig
Phase 1/2 Completed
NCT00002951 2013-09-05
Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer
University of Chicago
Phase 2 Completed
NCT00615927 2013-03-15
Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)
Duke University
Phase 2 Completed
NCT00613132 2013-02-20
Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG
Duke University
Phase 1 Completed
NCT00354913 2013-01-18
Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma
Duke University
Phase 2 Completed
NCT00613054 2012-12-05
Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma
Duke University
Phase 1 Completed
NCT00002940 2012-10-19
Hydroxyurea in Treating Patients With Epstein-Barr Virus-Associated Primary CNS Lymphoma and AIDS
St. Jude Children's Research Hospital
Phase 2 Completed
NCT01521299 2012-08-28
A Dose Escalation Study of Hydroxyurea in Combination With SCH900776 in Advanced Malignant Solid Tumors
Dartmouth-Hitchcock Medical Center
Phase 1 Withdrawn
NCT01645124 2012-07-20
CYTO-PV
Consorzio Mario Negri Sud
Phase 3 Terminated
NCT00004897 2012-06-12
Combination Chemotherapy and Interferon Alfa Followed by Surgery and/or Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer
Northwestern University
Phase 2 Terminated
NCT00002674 2010-04-02
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia
Fred Hutchinson Cancer Center
Phase 2 Completed